CM
RPTX

Caption Management’s Repare Therapeutics RPTX Stock Holding History

Caption Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-259,400
Closed -$3.13M – 1621
2023
Q3 		$3.13M Buy
+259,400
New +$2.68M 0.05% 464

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Caption Management's RPTX Position: Q4 2023 in Review

Caption Management sold out of Repare Therapeutics (RPTX) in Q4 2023, closing a stake of 87,085 shares — an estimated $1.05M sold.

Caption Management first reported a position in RPTX in Q3 2021 and held it in 2 quarters. The position peaked at $1.05M in Q3 2023. 69 funds tracked by Wall St. Rank hold RPTX as of Q4 2023.

  • Caption Management reported no remaining Repare Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Caption Management sold 87,085 Repare Therapeutics shares in Q4 2023, an estimated $1.05M.
  • Caption Management first reported a position in Repare Therapeutics in Q3 2021 and held it in 2 quarters.
  • Caption Management's Repare Therapeutics position peaked at $1.05M in Q3 2023.
  • 69 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2023.

Based on Caption Management's 13F filing for Q4 2023, filed 14 Feb 2024.